Perfeziona i miei risultati

Document type

Collection spécifique

Lingua

Université de Fribourg

Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial

Arroyo, Diego ; Togni, Mario ; Puricel, Serban ; Gerard, Baeriswyl ; Sonja, Lehmann ; Corpataux, Noé ; Villeneuve, Hélène ; Boute, Estelle ; Stauffer, Jean-Christophe ; Goy, Jean-Jacques ; Cook, Stéphane

In: Trials, 2014, vol. 15, no. 1, p. 9

Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The...

Université de Fribourg

A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: The CLO-CLO trial = Étude randomisée comparant la réactivité plaquettaire des patients traités par diverses préparations commerciales de clopidogrel. Étude CLO-CLO

Oberhänsli, Markus ; Lehner, Cédric ; Puricel, Serban ; Lehmann, Sonja ; Togni, Mario ; Stauffer, Jean-Christophe ; Baeriswyl, Gérard ; Goy, Jean-Jacques ; Cook, Stéphane

In: Archives of Cardiovascular Diseases, 2012, vol. 105, no. 11, p. 587–592

BackgroundThe salt linked to the clopidogrel molecule in generic preparations is suspected to affect its clinical efficacy. There is a lack of information about inhibition of platelet reactivity by generic preparations.AimsTo compare the effect of original clopidogrel (clopidogrel bisulphate [Plavix®]), generic clopidogrel preparations (clopidogrel hydrochloride...